English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Essex Invests $3.5 million in Abpro

Apr. 6, 2016

On April 6, 2016 Abpro, an integrated life science company at the forefront of synthetic biology, announced its partnership with Essex Bio, a China-based biopharmaceutical company. Abpro and Essex will co-develop multiple monoclonal antibodies in immuno-oncology and ophthalmology by leveraging Abpro’s DiversImmune™ platform.

In the context of the transaction, Abpro received a $3.5M equity investment from Essex Bio and an undisclosed amount from affiliates.